Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Apr, 2016 | Pages:
75 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Contact Dermatitis - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Contact Dermatitis - Pipeline Review, H1 2016', provides an overview of the Contact Dermatitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Contact Dermatitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Contact Dermatitis and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Contact Dermatitis - The report reviews pipeline therapeutics for Contact Dermatitis by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Contact Dermatitis therapeutics and enlists all their major and minor projects - The report assesses Contact Dermatitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Contact Dermatitis Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Contact Dermatitis - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Contact Dermatitis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Content 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Contact Dermatitis Overview 7 Therapeutics Development 8 Pipeline Products for Contact Dermatitis - Overview 8 Contact Dermatitis - Therapeutics under Development by Companies 9 Contact Dermatitis - Pipeline Products Glance 11 Clinical Stage Products 11 Early Stage Products 12 Contact Dermatitis - Products under Development by Companies 13 Contact Dermatitis - Companies Involved in Therapeutics Development 14 Aldeyra Therapeutics, Inc. 14 Anacor Pharmaceuticals, Inc. 15 AskAt Inc. 16 Brickell Biotech, Inc. 17 Dr. August Wolff GmbH & Co. KG Arzneimittle 18 Hapten Sciences, Inc. 19 ILiAD Biotechnologies, LLC 20 LegoChem Biosciences, Inc 21 Marinomed Biotechnologie GmbH 22 Novartis AG 23 Signum Dermalogix, Inc 24 Sucampo Pharmaceuticals, Inc. 25 Contact Dermatitis - Therapeutics Assessment 26 Assessment by Monotherapy Products 26 Assessment by Target 27 Assessment by Mechanism of Action 29 Assessment by Route of Administration 31 Assessment by Molecule Type 33 Drug Profiles 35 AAT-008 - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 AN-3485 - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 BBI-2000 - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 beta-escin - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 grapiprant - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 HPT-721 - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 LCB-030110 - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 NS-2 - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 pertussis [strain BPZE1] vaccine - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 RTU-1096 - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 secukinumab - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 SIG-1322 - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 WOL-071007 - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 Contact Dermatitis - Recent Pipeline Updates 57 Contact Dermatitis - Dormant Projects 71 Contact Dermatitis - Discontinued Products 72 Contact Dermatitis - Product Development Milestones 73 Featured News & Press Releases 73 Nov 19, 2015: Hapten Sciences to Begin Clinical Trials for Novel Poison Ivy Vaccine 73 Appendix 74 Methodology 74 Coverage 74 Secondary Research 74 Primary Research 74 Expert Panel Validation 74 Contact Us 74 Disclaimer 75
List of Tables
Number of Products under Development for Contact Dermatitis, H1 2016 8 Number of Products under Development by Companies, H1 2016 10 Comparative Analysis by Clinical Stage Development, H1 2016 11 Comparative Analysis by Early Stage Development, H1 2016 12 Products under Development by Companies, H1 2016 13 Contact Dermatitis - Pipeline by Aldeyra Therapeutics, Inc., H1 2016 14 Contact Dermatitis - Pipeline by Anacor Pharmaceuticals, Inc., H1 2016 15 Contact Dermatitis - Pipeline by AskAt Inc., H1 2016 16 Contact Dermatitis - Pipeline by Brickell Biotech, Inc., H1 2016 17 Contact Dermatitis - Pipeline by Dr. August Wolff GmbH & Co. KG Arzneimittle, H1 2016 18 Contact Dermatitis - Pipeline by Hapten Sciences, Inc., H1 2016 19 Contact Dermatitis - Pipeline by ILiAD Biotechnologies, LLC, H1 2016 20 Contact Dermatitis - Pipeline by LegoChem Biosciences, Inc, H1 2016 21 Contact Dermatitis - Pipeline by Marinomed Biotechnologie GmbH, H1 2016 22 Contact Dermatitis - Pipeline by Novartis AG, H1 2016 23 Contact Dermatitis - Pipeline by Signum Dermalogix, Inc, H1 2016 24 Contact Dermatitis - Pipeline by Sucampo Pharmaceuticals, Inc., H1 2016 25 Assessment by Monotherapy Products, H1 2016 26 Number of Products by Stage and Target, H1 2016 28 Number of Products by Stage and Mechanism of Action, H1 2016 30 Number of Products by Stage and Route of Administration, H1 2016 32 Number of Products by Stage and Molecule Type, H1 2016 34 Contact Dermatitis Therapeutics - Recent Pipeline Updates, H1 2016 57 Contact Dermatitis - Dormant Projects, H1 2016 71 Contact Dermatitis - Discontinued Products, H1 2016 72
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
